ResearcherShanghai Jiao Tong UniversityNo recent work listed
Jiayu Yao
Matched on ORCID iD 0000-0003-0344-0813; OpenAlex author ID A5101756522. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2021: 2 papers · 2022: 6 papers
Papers 8
- Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
- Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
- Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
- Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. Co-author DOI 10.18632/aging.204031↗
- A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
- Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
- Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
- A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Co-author DOI 10.21037/tcr-20-3478↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tiebo Mao · 8 shared papers, 2021–2022 · strength 0.97
- Paper Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. DOI 10.18632/aging.204031↗
- Paper A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. DOI 10.3389/fcell.2022.1001606↗
- Paper Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. DOI 10.3389/fcell.2022.942225↗
- Xiaofei Zhang · 7 shared papers, 2021–2022 · strength 0.85
- Paper Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. DOI 10.18632/aging.204031↗
- Paper A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. DOI 10.3389/fcell.2022.1001606↗
- Paper Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. DOI 10.3389/fcell.2022.942225↗
- Jiujie Cui · 7 shared papers, 2021–2022 · strength 0.84
- Paper A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. DOI 10.3389/fcell.2022.1001606↗
- Paper Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. DOI 10.3389/fcell.2022.942225↗
- Paper A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated adv… DOI 10.21037/tcr-20-3478↗
- Weiyu Ge · 5 shared papers, 2022 · strength 0.64
- Paper Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. DOI 10.18632/aging.204031↗
- Paper A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. DOI 10.3389/fcell.2022.1001606↗
- Paper Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. DOI 10.3389/fcell.2022.942225↗
- Liwei Wang · 4 shared papers, 2022 · strength 0.48
- Paper Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. DOI 10.18632/aging.204031↗
- Paper Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. DOI 10.1155/2022/5634887↗
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Feng Jiao · 4 shared papers, 2021–2022 · strength 0.45
- Paper A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated adv… DOI 10.21037/tcr-20-3478↗
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Shengbai Xue · 3 shared papers, 2022 · strength 0.39
- Paper A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. DOI 10.3389/fcell.2022.1001606↗
- Paper Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. DOI 10.3389/fcell.2022.942225↗
- Paper Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. DOI 10.1155/2022/5634887↗
- Jiong Hu · 3 shared papers, 2021–2022 · strength 0.32
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Yongwei Sun · 3 shared papers, 2021–2022 · strength 0.32
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Deliang Fu · 3 shared papers, 2021–2022 · strength 0.32
- Paper Characterization of DNA damage response deficiency in pancreatic cancer patients from China. DOI 10.1002/cac2.12238↗
- Paper Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. DOI 10.1016/j.ebiom.2022.103897↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Yanling Wang · 2 shared papers, 2022 · strength 0.26
- Liwei Wang · 2 shared papers, 2022 · strength 0.26
- Shumin Li · 2 shared papers, 2022 · strength 0.25
- Liwei Wang · 2 shared papers, 2021 · strength 0.23
- Paper A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated adv… DOI 10.21037/tcr-20-3478↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Yiyi Liang · 2 shared papers, 2021 · strength 0.23
- Paper A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated adv… DOI 10.21037/tcr-20-3478↗
- Paper Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor pro… DOI 10.1038/s41421-021-00271-4↗
- Yingbin Liu · 2 shared papers, 2022 · strength 0.22
- Yuexiang Wang · 2 shared papers, 2022 · strength 0.22
- Yu Wang · 2 shared papers, 2021–2022 · strength 0.21
- Haiyan Yang · 1 shared paper, 2021 · strength 0.13
- Yanling Wang · 1 shared paper, 2022 · strength 0.13
- Yu Wang · 1 shared paper, 2022 · strength 0.11
- Qiang Liu · 1 shared paper, 2022 · strength 0.11
- Qing Xia · 1 shared paper, 2021 · strength 0.10
- Jing Xue · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.